We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC‐guided dosing in nonsmall cell lung cancer.
- Authors
Ma, Yuxiang; Zhao, Xin; Chen, Xi; Huang, Xinxin; Lin, Qingguang; Lin, Yuehao; Salamone, Salvatore J; Zhou, Xinlan; Wang, Changzheng; Liang, Weiting; Zhao, Hongyun; Wu, Kui; Yang, Yunpeng; Zhang, Li
- Abstract
In total, patients received 175 cycles in arm A, and 137 cycles in arm B. Most patients who discontinued early were affected by toxicities in arm B (28.6% vs. 12.0%, I p i = 0.040). Dear Editor, The current study is aimed to achieve precision medicine for docetaxel chemotherapy in nonsmall cell lung cancer (NSCLC) by pharmacokinetic (PK)- and pharmacogenetic (PG)-based therapeutic drug monitoring (TDM). Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC-guided dosing in nonsmall cell lung cancer.
- Subjects
NON-small-cell lung carcinoma; DRUG monitoring; DOCETAXEL; CLINICAL trials; PHARMACOGENOMICS; PHARMACOKINETICS
- Publication
Clinical & Translational Medicine, 2021, Vol 11, Issue 4, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.354